BOSTON--(BUSINESS WIRE)--Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced that data related to galeterone will be presented in two posters at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place from June 3-7, 2016, in Chicago. Galeterone, Tokai’s lead product candidate, is being developed for the treatment of men with metastatic castration-resistance prostate cancer.
